Department of Laboratory Medicine, First Affiliated Hospital of Huzhou University, Huzhou, 313000, Zhejiang, China.
Department of Pathology, First Affiliated Hospital of Huzhou University, Huzhou, 313000, Zhejiang, China.
BMC Cancer. 2024 Nov 9;24(1):1371. doi: 10.1186/s12885-024-13144-2.
Long non-coding RNAs (lncRNAs) have a notable role in the diagnosis and prognosis of cancer. However, the associations between lncRNA-related hub genes (LRHGs) expression and the corresponding outcomes have not been fully understood in lung adenocarcinoma (LUAD). Here, a total of 71 patients diagnosed with LUAD and 60 healthy volunteers at The First Affiliated Hospital of Huzhou University from April, 2023 to December, 2023 were enrolled in the present study. A LRHGs model was established using least absolute shrinkage and selection operator analyses of The Cancer Genome Atlas-LUAD datasets. The underlying mechanisms of the LRHGs were investigated via Gene Set Enrichment Analysis and Gene Set Variation Analysis. Additionally, the diagnostic role of serum HOXD cluster antisense RNA 2 (HOXD-AS2) was assessed by receiver operating characteristic (ROC) curve analysis. Lastly, TCGA-LUAD samples were divided into high- and low-HOXD-AS2 expression groups based on the median expression. The associations between HOXD-AS2 expression and miR-4538 as well as Calmodulin-Dependent Protein Kinase Type II subunit Beta (CAMK2B) levels were conducted through Pearson correlation analysis. A comprehensive analysis identified 141 differentially expressed lncRNAs between 539 LUAD tissues and 59 normal samples. A prognostic marker for overall survival was established by constructing a predictive signature consisting of 9 LRHGs. Subsequently, 474 LUAD samples were categorized into a high or low-risk group based on the median of the risk score. An independent prognostic model was constructed to confirm the validity of this categorization. Further comparisons of the clinicopathological features and LRHG-related pathways were performed between the two groups. Examinations of LRHG expression in two LUAD clusters and of the association between LRHG expression and immune infiltration were also conducted. HOXD-AS2 expression was shown to be elevated in LUAD tissues compared with matched normal tissues, and the serum HOXD-AS2 level was also notably increased in LUAD samples compared with healthy controls. The results of the ROC analysis indicated that the sensitivity and specificity of HOXD-AS2 were higher than that of cytokeratin-19 fragment (CYFRA21-1), which is a serum marker for LUAD. Pearson analyses indicated that miR-4538 level was negatively associated with HOXD-AS2 expression, but CAMK2B level showed positive correlation in LUAD. The results of the present study therefore indicated that the constructed LRHG model, particularly HOXD-AS2, could independently diagnose and predict the prognosis of LUAD, which suggested the underlying mechanism of the HOXD-AS2/miR-4538/CAMK2B, and might offer efficient strategies for LUAD treatment.
长链非编码 RNA(lncRNA)在癌症的诊断和预后中具有显著作用。然而,lncRNA 相关枢纽基因(LRHG)表达与肺腺癌(LUAD)相应结果之间的关联尚未完全阐明。本研究共纳入了 2023 年 4 月至 2023 年 12 月在湖州大学第一附属医院诊断为 LUAD 的 71 例患者和 60 名健康志愿者。使用癌症基因组图谱-LUAD 数据集的最小绝对收缩和选择算子分析建立了 LRHG 模型。通过基因集富集分析和基因集变异分析研究了 LRHG 的潜在机制。此外,通过接收者操作特征(ROC)曲线分析评估了血清 HOXD 簇反义 RNA 2(HOXD-AS2)的诊断作用。最后,根据中位数表达,将 TCGA-LUAD 样本分为高表达和低表达 HOXD-AS2 组。通过 Pearson 相关性分析,对 HOXD-AS2 表达与 miR-4538 以及钙调蛋白依赖性蛋白激酶 II 亚基β(CAMK2B)水平之间的关系进行了研究。综合分析确定了 539 例 LUAD 组织和 59 例正常样本之间的 141 个差异表达 lncRNA。通过构建由 9 个 LRHG 组成的预测特征,建立了用于总体生存的预后标志物。随后,根据风险评分的中位数,将 474 例 LUAD 样本分为高风险或低风险组。构建了一个独立的预后模型来确认这种分类的有效性。进一步比较了两组之间的临床病理特征和 LRHG 相关通路。还对两个 LUAD 簇中的 LRHG 表达进行了检查,并对 LRHG 表达与免疫浸润之间的关系进行了研究。与匹配的正常组织相比,LUAD 组织中 HOXD-AS2 的表达升高,与健康对照组相比,LUAD 样本中的血清 HOXD-AS2 水平也显著升高。ROC 分析结果表明,HOXD-AS2 的敏感性和特异性均高于 LUAD 的血清标志物细胞角蛋白 19 片段(CYFRA21-1)。Pearson 分析表明,miR-4538 水平与 HOXD-AS2 表达呈负相关,而在 LUAD 中 CAMK2B 水平呈正相关。因此,本研究结果表明,构建的 LRHG 模型,特别是 HOXD-AS2,可以独立诊断和预测 LUAD 的预后,这提示了 HOXD-AS2/miR-4538/CAMK2B 的潜在机制,并可能为 LUAD 的治疗提供有效的策略。
Clin Respir J. 2024-8
Aging (Albany NY). 2024-6-10
J Cancer Res Clin Oncol. 2024-5-26
J Cancer Res Clin Oncol. 2024-4-1